CAJ | 학술논문

目的：评估卡泊芬净治疗恶性血液病合并侵袭性肺曲霉菌(IPA)感染的临床疗效和安全性。方法：2008年1月-2012年12月恶性血液病合并IPA感染患者49例，所有患者均经CT检查和GM试验临床诊断；采用注射用醋酸卡泊芬净进行治疗，根据临床疗效标准，评价卡泊芬净治疗的疗效和安全性。结果：49例患者的治疗总有效率为91.84%(45/49)。卡泊芬净治疗过程中9例发生不良反应，不良反应发生率为18.37%。结论：卡泊芬净有很好的抗真菌活性，是治疗恶性血液病合并肺曲霉菌感染安全有效的药物。
목적：평고잡박분정치료악성혈액병합병침습성폐곡매균(IPA)감염적림상료효화안전성。방법：2008년1월-2012년12월악성혈액병합병IPA감염환자49례，소유환자균경CT검사화GM시험림상진단；채용주사용작산잡박분정진행치료，근거림상료효표준，평개잡박분정치료적료효화안전성。결과：49례환자적치료총유효솔위91.84%(45/49)。잡박분정치료과정중9례발생불량반응，불량반응발생솔위18.37%。결론：잡박분정유흔호적항진균활성，시치료악성혈액병합병폐곡매균감염안전유효적약물。
Objective:To evaluate the clinical efficacy and safety of caspofungin in treatment of hematological malignanciescombinedinvasivepulmonaryaspergillosis(IPA)infection.Methods:49hematologicalmalignanciescombined IPA infection patients (2008.1-2012.12) that were diagnosed by CT and galactomannan test were treated with caspofungin. The clinical efficacy and safety of caspofungin were evaluated according to clinical curative effect standard.Results:The total effective rate of 49 patients was 91.84%(45/49) after caspofungin treatment;and the incidence of drug related adverse events was 18.37%(9/49).Conclusions:Caspofungin has good antifungal activity, and it is a safe and effective drug for treating hematological malignancies combinedIPAinfection.